Tangen Gets BARDA Funding for an Anthrax Assay

Tangen Biosciences has received a $3.3 million award from the Biomedical Advanced Research and Development Authority (BARDA) to develop an anthrax diagnostic assay.

The BARDA funding will support a clinical trial for a bloodstream-anthrax diagnostic that uses the company’s TangenDx platform.

Tangen said the research on the anthrax diagnostic will be expanded to develop an antimicrobial resistance assay.